<html><body><pre>
[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5274 Referred in Senate (RFS)]

&lt;DOC&gt;
117th CONGRESS
  2d Session
                                H. R. 5274


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             July 14, 2022

Received; read twice and referred to the Committee on Homeland Security 
                        and Governmental Affairs

_______________________________________________________________________

                                 AN ACT


 
To amend the Homeland Security Act of 2002 to provide training for U.S. 
   Customs and Border Protection personnel on the use of containment 
devices to prevent secondary exposure to fentanyl and other potentially 
               lethal substances, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Prevent Exposure to Narcotics and 
Toxics Act of 2021'' or the ``PREVENT ACT of 2021''.

SEC. 2. PROVIDING TRAINING FOR U.S. CUSTOMS AND BORDER PROTECTION 
              PERSONNEL ON THE USE OF CONTAINMENT DEVICES TO PREVENT 
              SECONDARY EXPOSURE TO FENTANYL AND OTHER POTENTIALLY 
              LETHAL SUBSTANCES.

    (a) Training.--Paragraph (1) of section 416(b) of the Homeland 
Security Act of 2002 (6 U.S.C. 216(b)) is amended by adding at the end 
the following new subparagraph:
                    ``(C) How to use containment devices to prevent 
                secondary exposure to fentanyl and other potentially 
                lethal substances.''.
    (b) Availability of Containment Devices.--Section 416(c) of the 
Homeland Security Act of 2002 (6 U.S.C. 216(c)) is amended--
            (1) by striking ``and'' after ``equipment'' and inserting a 
        comma; and
            (2) by inserting ``and containment devices'' after 
        ``naloxone,''.

            Passed the House of Representatives July 13, 2022.

            Attest:

                                             CHERYL L. JOHNSON,

                                                                 Clerk.
</pre></body></html>
